Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
3.578(c) 3.52(c) 3.719(c) 3.95(c) 5.084(c) Last
2 172 498 825 884 1 726 800 2 434 983 9 211 211 Volume
+2.23% -1.62% +5.65% +6.21% +28.71% Change
More quotes
Estimated financial data (e)
Sales 2021 112 M 126 M 126 M
Net income 2021 70,0 M 79,2 M 79,2 M
Net cash position 2021 90,4 M 102 M 102 M
P/E ratio 2021 5,84x
Yield 2021 -
Sales 2022 86,6 M 98,1 M 98,1 M
Net income 2022 18,0 M 20,4 M 20,4 M
Net cash position 2022 190 M 215 M 215 M
P/E ratio 2022 23,1x
Yield 2022 -
Capitalization 359 M 406 M 406 M
EV / Sales 2021 2,40x
EV / Sales 2022 1,95x
Nbr of Employees 174
Free-Float 99,4%
More Financials
Company
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of... 
More about the company
Ratings of Novacyt
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NOVACYT
11/26EUROPEAN MIDDAY BRIEFING - Stocks, Oil Drop on Concerns Over New Covid-19 Variant
DJ
11/26MASIH YAZDI : EUROPEAN MIDDAY BRIEFING - Stocks, Oil Drop on -2-
DJ
11/26Novacyt Secures UK Nod For COVID-19 Test
MT
11/02Novacyt Flags Revenue Hit as UK Regulator Clears Only Two COVID-19 Tests
MT
11/02BP's Underlying Results Seen as Decent
DJ
11/02FTSE 100 Falls in Early Trade; Flutter, BP Slide
DJ
11/02London Stocks Seen Opening Lower; BP in Focus
DJ
11/02Novacyt S.A. Announces Validation of Covid-19 Tests in the UK Under CTDA Legislation
CI
10/19NOVACYT : Results of Annual General Meeting
PU
10/16NOVACYT : 2021 agm
PU
10/01NOVACYT : Convening notice for 18th October 2021
PU
09/30NOVACYT : Launches Two New PCR Tests for COVID-19, Other Winter Viruses
MT
09/30NOVACYT : R&D update
PU
09/30NOVACYT S.A.(ENXTPA : ALNOV) dropped from Next Biotech Index
CI
09/29NOVACYT : Notice of AGM
PU
More news
News in other languages on NOVACYT
11/26NOVACYT : bondit grâce au nouveau variant et au Royaume-Uni
11/26CAC40 : le nouveau variant Covid fait plier les cours
11/26Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 26 novembre 2021
11/26B.1.1.529 fait tanguer les marchés
11/26Novacyt obtient le feu vert du Royaume-Uni pour le test COVID-19
More news
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 5,08 €
Average target price 4,10 €
Spread / Average Target -19,4%
EPS Revisions
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-48.12%406
MODERNA, INC.215.53%133 648
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416